Peter Greenleaf, Aurinia CEO
After passing on Acceleron, Bristol Myers eyes bolt-on acquisition of autoimmune specialist — report
Bristol Myers Squibb is looking to beef up its autoimmune portfolio by scooping up Aurinia Pharmaceuticals, Bloomberg reported.
The recent overtures to Aurinia, relayed by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.